Takeda Pharmaceutical envisions a potentially significant market in polycythemia vera (PV) for rusfertide, which it is developing together with Protagonist Therapeutics, after reporting positive Phase III data for the drug. Rusfertide particularly stands to benefit from the more than three-quarters of patients with PV who have uncontrolled hematocrit levels.
Takeda/Protagonist’s Rusfertide Could Be A Main Character In PV After Phase III Data
The companies announced positive data from the VERIFY study among patients with PV, showing lower proportions of patients requiring phlebotomy.
